The PRISMA 2020 statement: an updated guideline for reporting systematic reviews
The reporting standard for systematic reviews: a 27-item checklist, an abstract checklist, and revised flow diagrams, replacing PRISMA 2009 — which by August 2020 had over 60,000 citations, endorsement from ~200 journals, and observational evidence associating its use with more complete reporting. The scope line is drawn precisely: PRISMA governs reporting, not conduct (Cochrane Handbook et al.), not quality appraisal (AMSTAR 2, ROBIS), not protocols (PRISMA-P) — it is the layer at which a review becomes checkable by outsiders. It applies with or without meta-analysis, to updated and living reviews, and anchors a family of extensions (network meta-analysis, scoping reviews, search reporting via PRISMA-S).
Development is itself protocol-shaped, following EQUATOR guidance: studies of where 2009 items were reported incompletely, a 60-document item bank of existing guidance, a survey of 110 methodologists and editors, a 21-member consensus meeting (Edinburgh 2018), five circulated revisions, and a layout-feedback round. The 26-author list publishes its competing-interest entanglements — editors-in-chief of the very journals endorsing the guideline — in a competing-interests statement the checklist itself now mandates of reviews (item 26).
What changed, and what it signals
The noteworthy changes are a transparency ratchet: full search strategies for all databases (2009 asked for at least one); near-miss exclusions cited with reasons (item 16b — studies that appear to meet criteria but were excluded); how many reviewers screened and extracted, whether independently, and details of any automation tools used (items 8–9); certainty-of-evidence assessment (15, 22); data, code, and materials availability (27); protocol registration or an explicit statement of its absence (24). The glossary is load-bearing: report vs record vs study disambiguates the units a flow diagram counts.
The discussion is candid about the enforcement gap: of 31 proposed interventions to increase guideline adherence, only 11 have been evaluated, mostly in confounded observational studies — the standard is consensus-strong but its causal effect on reporting quality is thinner than its citation count suggests.
Assessment
- Durable: reporting as the enforceable quality surface; the reporting/conduct/appraisal separation; item 16b’s excluded-with-reasons discipline; the automation-disclosure items, written for ML screening tools but exactly fitted to agent-run reviews; registration-or-say-so.
- Era-bound: the specific item wording (a PRISMA 2030 is the pattern’s own prediction); the medicine-centered scope language.
- Caveats: effectiveness evidence is observational and mixed, by the authors’ own accounting; checklist compliance can be performed without substance — the items verify presence of disclosures, not their honesty.
- In this library: the reporting phase of kitchenham2007 matured into an enforced, versioned artifact — and the map for the survey layer’s deposition gate: a garden survey’s frozen record should be able to answer PRISMA’s items (search strategies in the audited logs, 16b in the disposition-coded catalog, items 8–9 as agent-pass disclosure, item 27 trivially by construction). The co-publication mechanics matter here too: the capture is the PLoS co-publication because the BMJ version of record blocks non-browser clients — multiple simultaneous DOIs for one work, handled as one identity with the BMJ DOI primary.